- Home
- JILL vs DSGN Comparison
JILL vs DSGN Comparison
Compare JILL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JILL
- DSGN
- Stock Information
- Founded
- JILL 1959
- DSGN 2017
- Country
- JILL United States
- DSGN United States
- Employees
- JILL N/A
- DSGN N/A
- Industry
- JILL Clothing/Shoe/Accessory Stores
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- JILL Consumer Discretionary
- DSGN Health Care
- Exchange
- JILL Nasdaq
- DSGN Nasdaq
- Market Cap
- JILL 233.1M
- DSGN 208.9M
- IPO Year
- JILL 2017
- DSGN 2021
- Fundamental
- Price
- JILL $18.17
- DSGN $5.82
- Analyst Decision
- JILL Buy
- DSGN
- Analyst Count
- JILL 3
- DSGN 0
- Target Price
- JILL $18.00
- DSGN N/A
- AVG Volume (30 Days)
- JILL 120.3K
- DSGN 184.3K
- Earning Date
- JILL 09-03-2025
- DSGN 11-06-2025
- Dividend Yield
- JILL 1.78%
- DSGN N/A
- EPS Growth
- JILL N/A
- DSGN N/A
- EPS
- JILL 2.39
- DSGN N/A
- Revenue
- JILL $601,713,000.00
- DSGN N/A
- Revenue This Year
- JILL $1.16
- DSGN N/A
- Revenue Next Year
- JILL $1.46
- DSGN N/A
- P/E Ratio
- JILL $7.54
- DSGN N/A
- Revenue Growth
- JILL N/A
- DSGN N/A
- 52 Week Low
- JILL $13.36
- DSGN $2.60
- 52 Week High
- JILL $30.40
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- JILL 66.54
- DSGN 59.68
- Support Level
- JILL $15.97
- DSGN $4.92
- Resistance Level
- JILL $18.38
- DSGN $6.57
- Average True Range (ATR)
- JILL 0.82
- DSGN 0.46
- MACD
- JILL 0.15
- DSGN 0.05
- Stochastic Oscillator
- JILL 92.03
- DSGN 60.48
About JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.